- Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era
May 4, 2026
Quick Read
Pfizer (PFE) posted Q4 adjusted EPS of $0.66 beating the $0.57 consensus on $17.56B in revenue while its non-COVID portfolio grew 9% operationally, led by Abrysvo (+136%) and Lorbrena (+45%), plus a $7.0B Metsera acquisition for obesity drugs with 20 planned pivotal trials in 2026. Moderna (MRNA) reported Q4 revenue of $678M (down 29% YoY) and a loss per share of $2.11 (beating the $2.62 estimate) while cutting approximately $2.2B in annual operating expenses and expanding international manufacturing across the UK, Australia, and Canada. Pfizer is pivoting toward a diversified pharma strategy anchored in obesity and oncology with near-term catalysts, while Moderna is betting everything on mRNA platform breadth through oncology partnerships and pipeline expansion after its COVID revenue cliff. The analyst who called NVIDIA in 2010 just named his top 10 stocks and Moderna wasn't one of them. Get them here FREE.
Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on a diversified non-COVID portfolio and a fresh push into obesity drugs.
Moderna leaned on cost cuts and international expansion to soften a steep COVID revenue cliff. Two very different pharma stories, both shaped by life after the pandemic windfall.
The analyst who called NVIDIA in 2010 just named his top 10 stocks and Moderna wasn't one of them.Get them here FREE.
Diversified Drugmaker Beats. mRNA Pure-Play Survives.
Pfizer posted adjusted EPS of $0.66 against a $0.57 consensus on $17.56 billion in revenue, with the top line dipping just 1.2% year over year. The non-COVID book did the heavy lifting, growing 9% operationally.
Standouts included Abrysvo at +136% and Lorbrena at +45%. The bruise: a $4.4 billion non-cash impairment tied to pipeline revisions dragged the GAAP line into a $1.65 billion net loss. Ugly optics, but largely accounting noise.
Moderna told a leaner story. Revenue landed at $678 million, down 29.08% year over year, while the loss per share of $2.11 still beat the $2.62 estimate.
CEO Stéphane Bancel pointed to "approximately $2.2 billion" in annual operating expense reductions, calling out three new international manufacturing sites in the UK, Australia, and Canada. The product story is thin: Spikevax, mNEXSPIKE, and mRESVIA. The pipeline story is wide.24/7 Wall St.
Obesity Bets vs Oncology mRNA
Pfizer's strategic pivot is unmistakable. Albert Bourla closed the $7 billion Metsera deal for ultra-long-acting GLP-1 obesity assets and is planning 10 pivotal trial starts in 2026 from that platform alone. He framed 2026 as "an important year rich in key catalysts" with roughly 20 pivotal study starts.
Story Continues
Lens Pfizer Moderna Market Cap ~$151.9B ~$18.2B Forward P/E 9x 23x Dividend Yield 6.55% None 1-Year Return +17.36% +60.97% Core Bet Obesity, oncology, vaccines mRNA platform breadth
Moderna is doubling down on what it knows: mRNA. The intismeran autogene melanoma program with Merck showed a 49% reduction in risk of recurrence or death versus Keytruda alone in the five-year Phase 2b readout. The science is persuasive, though the FDA refusal-to-file letter on the mRNA-1010 flu vaccine remains a clear overhang.Joe Raedle / Getty Images News via Getty Images
The Next Test Is Catalyst Execution
Pfizer guides 2026 revenue to $59.5 to $62.5 billion and adjusted EPS of $2.80 to $3, baking in $1.5 billion in loss-of-exclusivity headwinds plus Most-Favored-Nation pricing pressure. Bourla's recent phantom stock unit acquisitions through April 2026 read as quiet confidence.
Moderna projects up to 10% revenue growth with cash falling to $5.5 to $6 billion, after drawing $600 million on a $1.5 billion credit facility. Norovirus Phase 3 data and propionic acidemia readouts are the catalysts I would circle.
Why I Lean Toward Pfizer for Steady Hands, Moderna for Risk Tolerance
For me, Pfizer fits the income-and-stability investor. A 6.55% yield, a forward P/E of 9x, and a real obesity and oncology pipeline give it room to compound.
Moderna is a different animal: a binary catalyst stock, up 55.78% year to date on hopes that melanoma data and international growth offset US weakness. For defensive pharma exposure with cash flow, Pfizer screens better on the numbers. Moderna's profile fits a higher-risk, catalyst-driven setup, with bigger upside tied to a platform breakout. Moderna's setup arguably hinges on the FDA flu situation clearing.
The analyst who called NVIDIA in 2010 just named his top 10 AI stocks
This analyst's 2025 picks are up 106% on average. He just named his top 10 stocks to buy in 2026. Get them here FREE.
View Comments
- Novo Nordisk vs. Pfizer: Which Healthcare Giant Is the Better Bet?
Apr 27, 2026
Novo Nordisk NVO and Pfizer PFE are both pharmaceutical giants based in Denmark and the United States, respectively, with strong leadership positions in distinct therapeutic areas. NVO is widely recognized as the market leader in the GLP-1 space, marketing its semaglutide drugs under brand names Ozempic (pre-filled pen) and Rybelsus (oral tablet) for type II diabetes (T2D), and Wegovy (injection and oral tablet) for chronic weight management.
Pfizer, traditionally strongest in oncology, where the segment accounts for roughly 27% of its total revenues, also maintains solid depth across inflammation, immunology, rare diseases and vaccines. But a recent strategic shift has brought Pfizer into much closer comparison with Novo Nordisk, as the company re-entered the obesity arena after winning a high-profile bidding war against NVO for the acquisition of Metsera, ultimately sealing the deal in late 2025.
The Metsera acquisition puts Pfizer back on the offensive in the lucrative obesity space after it scrapped the development of danuglipron, a weight-loss pill, earlier in 2025. With both companies now positioned in obesity — one defending its lead and the other mounting a fresh challenge — NVO and PFE have become increasingly comparable from an investment standpoint.
But which stock presents a better investment opportunity right now? Let’s dive into their fundamentals, growth outlook and potential challenges to make a well-informed comparison.
The Case for NVO Stock
Novo Nordisk has achieved tremendous success in the cardiometabolic treatment space, driven primarily by its semaglutide medicines, Ozempic, Rybelsus and Wegovy. As of December 2025-end, Novo Nordisk remained the market leader with a total GLP-1 volume market share of 54.6% globally across diabetes and obesity care.
NVO has been investing heavily to expand its manufacturing capacity as part of its strategic move to strengthen its leadership in the diabetes and obesity care market for its GLP-1 products.
Novo Nordisk is pursuing new indications for its semaglutide drugs, including CV and other indications. In 2025, Rybelsus became the first oral therapy approved in the United States to lower the risk of major adverse CV events in high-risk T2D patients, regardless of prior CV history. Wegovy’s label includes CV, HFpEF and osteoarthritis indications, while Ozempic remains the only GLP-1 approved to slow kidney disease and reduce CV death in patients with diabetes. Higher-dose Wegovy injections have been approved in the United States and the EU, expanding its portfolio and enabling the company to tailor treatment options better to meet the diverse needs and preferences of obesity patients. NVO is also seeking to expand Ozempic’s label to include peripheral artery disease.
Story Continues
In late December, the FDA also approved NVO’s 25 mg oral semaglutide (Wegovy pill) for obesity and CV disease, which was subsequently launched in early January. The FDA recently approved an oral version of Ozempic (1.5 mg, 4 mg and 9 mg) for adult T2D patients, which NVO is planning to launch in the second quarter of 2026. A supplemental application for a higher 25 mg tablet is also under review, with a regulatory decision expected by the end of 2026. Novo Nordisk also intends to seek regulatory approval for both Rybelsus and oral Ozempic in children and adolescents aged 10 to 17 years with T2D, in the United States and the EU, in the second half of 2026.
Novo Nordisk is advancing its next-generation obesity pipeline. It has submitted a regulatory filing seeking the approval of CagriSema injection, a follow-up drug to Wegovy, for obesity. Meanwhile, its mid-stage asset, amycretin, has shown strong weight-loss efficacy in a phase II study and is slated to enter phase III soon. The company has bolstered its pipeline through several major collaborations and acquisition deals.
Beyond GLP-1s, NVO is building its Rare Disease franchise, advancing Mim8 in hemophilia A, and securing both EU and U.S. approvals for Alhemo to treat hemophilia A and B, with or without inhibitors. Meanwhile, the FDA has granted accelerated approval for Wegovy in treating MASH with fibrosis. Novo Nordisk and rival Eli Lilly LLY have also introduced multiple price cuts in response to pressure from the U.S. government during 2025 and 2026 to improve patient access to GLP-1 medicines.
Despite the recent wins, Novo Nordisk is far from being out of the woods yet. It has been facing increasing competition from Eli Lilly, which markets its tirzepatide (GLP-1) medicines as Mounjaro for T2D and Zepbound for obesity. Despite being on the market for just over three years, these drugs have become LLY’s key top-line drivers. Lilly recently secured FDA approval of its oral GLP-1 drug, orforglipron, for adults with obesity or overweight with weight-related medical problems, marketed under the brand name Foundayo. The drug competes directly with NVO’s Wegovy pill.
Though Novo Nordisk has been able to bring the compounded alternatives problem under control with help from the FDA and strategic deals with telehealth companies, it still faces mounting structural challenges, as is evident from its 2026 outlook, highlighting weak core momentum. Adjusted guidance points to declining sales and operating profit, as pricing pressure, rising competition and slowing U.S. demand weigh on performance. While international growth and the launch of oral Wegovy offer some support, increased costs and lack of one-off benefits limit upside, leaving investors doubtful about NVO’s ability to sustain its leadership in the evolving obesity market.
The Case for PFE Stock
Pfizer is one of the largest and most successful drugmakers in oncology. Its position in oncology was strengthened with the acquisition of Seagen in 2023. Its oncology revenues grew 8% in 2025, driven by drugs such as Xtandi, Lorbrena, the Braftovi-Mektovi combination, and Padcev.
Pfizer’s dependence on its COVID business has now reduced. Its non-COVID operational revenues are improving, driven by key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those from Seagen. Sales of Pfizer's recently launched and acquired products rose approximately 14% operationally year over year in 2025. In 2026, Pfizer expects its recently launched and acquired products to continue to record double-digit growth.
Pfizer is also trying to rebuild its pipeline through acquisitions. Seagen, Metsera and Biohaven are the most significant strategic acquisitions in recent years. In 2025, Pfizer invested around $9 billion in M&A deals, including the acquisition of obesity drugmaker, Metsera and the licensing deal with 3SBio.
Pfizer plans to start 20 pivotal studies in 2026, including 10 for the ultra-long-acting obesity candidates added from the Metsera acquisition and four for PF-08634404, the dual PD-1/VEGF inhibitor in-licensed from Chinese biotech 3SBio in 2025.
Pfizer expects its recently launched and acquired products and a strong pipeline to help revive top-line growth toward the end of the decade.
Pfizer’s significant cost reduction and efforts to improve R&D productivity measures are also driving profit growth. Pfizer’s dividend yield stands at around 6.3%, which is also impressive.
However, Pfizer’s 2026 outlook failed to impress investors. PFE’s revenue and earnings guidance for 2026 represents mostly flat to slightly negative growth, which disappointed investors. Its other challenges include declining sales of its COVID products, unfavorable impact from the Medicare Part D redesign and the upcoming loss-of-exclusivity cliff in the 2026-2030 period as several of its key products, including Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, face patent expirations.
How Do Estimates Compare for NVO & PFE?
The Zacks Consensus Estimate for Novo Nordisk’s 2026 sales and earnings per share (EPS) implies a year-over-year decline of around 3% and 16%, respectively. EPS estimates for 2026 have been trending downward over the past 60 days, while those for 2027 show slight improvement over the same period.
NVO Estimate MovementZacks Investment Research
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Pfizer’s 2025 sales and EPS implies a year-over-year decrease of about 2% and 7%, respectively. PFE’s EPS estimates for 2026 have been trending upward over the past 60 days, while those for 2027 show a slight decline over the same period.
PFE Estimate MovementZacks Investment Research
Image Source: Zacks Investment Research
Price Performance and Valuation of NVO & PFE
Year to date, shares of NVO have lost 19%, while those of PFE have gained 8.5%. In comparison, the industry has declined 6.4%, as seen in the chart below.Zacks Investment Research
Image Source: Zacks Investment Research
From a valuation standpoint, Novo Nordisk is more expensive than Pfizer, going by the price/earnings ratio. NVO’s shares currently trade at 12.32 times forward earnings, higher than 9.21 for PFE.Zacks Investment Research
Image Source: Zacks Investment Research
NVO vs. PFE: Which Stock Holds the Edge?
Novo Nordisk and Pfizer carry a Zacks Rank #3 (Hold) each at present, which makes choosing one stock a difficult task. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
However, Pfizer currently looks like the better pick than Novo Nordisk, as the obesity market is getting much more competitive. Novo Nordisk still leads with its GLP-1 drugs, but Eli Lilly is rapidly catching up with strong products and new launches, putting pressure on NVO’s growth and pricing power. This is already showing up in its 2026 outlook, where both sales and profits are expected to decline, raising concerns about how long it can maintain its leadership.
On the other hand, Pfizer looks more stable despite facing patent expiries. Its business is more diversified, with strong positions in oncology and other areas, so it isn’t relying on just one market like obesity. Even though growth may be modest, its earnings outlook is steadier, its valuation is cheaper, and the stock is less volatile. In comparison, Novo Nordisk faces bigger near-term uncertainty, making Pfizer the safer choice for investors right now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Pfizer Inc. (PFE): One of the Best Safe Stocks to Invest in for Beginners
Apr 24, 2026
We just covered the 15 Safe Stocks to Invest In For Beginners and Pfizer Inc. (NYSE:PFE) ranks 14th on this list.
Pfizer Inc. (NYSE:PFE) is expanding into the cancer treatment market. The $43 billion acquisition of Seagen has begun to pay off, with Pfizer now controlling a dominant share of the Antibody-Drug Conjugate (ADC) market, a category most high profile investors view as the next frontier of high-margin biotech. The firm plans to initiate 20 pivotal studies in 2026, including 10 for the obesity candidates acquired from Metsera and 4 for high-priority oncology assets. For 2026, Pfizer has guided for roughly $5 billion in COVID-related revenue. When excluding COVID products, the core portfolio of the firm grew 6% operationally in late 2025.Why agilon health (AGL) Is Doing a 1-for-25 Reverse Split to Stay NYSE-Compliant
The cost realignment and operational discipline of Pfizer Inc. (NYSE:PFE) must also be mentioned, two key metrics favored by defensive investors. The firm successfully executed a $4 billion cost-cutting program in 2025 and the smart money is betting that the current management, under increased scrutiny, will prioritize R&D efficiency over the scattered M&A of previous years. From a quantitative perspective, Pfizer is currently one of the cheapest mega-cap pharmaceutical stocks. The stock is trading at roughly 9.3x forward earnings, compared to an industry average of over 18x. With a dividend yield holding steady at around 6.2%, investors are using the stock as an income generator.
While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Israel Englander Stock Portfolio: Top 10 Stock Picks and Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential.
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- Pfizer CFO Dave Denton on Oncology, Obesity, and Pfizer’s Next Growth Cycle
Apr 22, 2026
Pfizer CFO Dave Denton goes Inside the ICE House to discuss how the company is navigating its post‑COVID transition and positioning itself for a return to sustainable growth later this decade. He details Pfizer’s major strategic investments in oncology and metabolic health, including the Seagen and Metsera deals, and explains how proven platforms, global scale, and financial discipline are central to those moves. Denton also shares how execution, patient‑centric innovation, and emerging technologies like AI are shaping the next chapter of Pfizer’s growth story.
View Comments
- Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
Apr 14, 2026
Structure Therapeutics Inc.
SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel. Mr. Lang joins Structure Therapeutics with more than fifteen years of executive leadership experience across global biopharmaceutical organizations, with deep expertise spanning legal, corporate strategy, compliance, risk management, and business development.
“Matt is a proven leader with a strong track record of guiding organizations through growth and transformation,” said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. “His experience across global operations, strategic transactions, and commercialization will be critical as we move aleniglipron into Phase 3 and continue to build a world-class leadership team.”
Mr. Lang most recently served as Chief Legal Officer and Secretary at Metsera, Inc., helping to guide the company through its up to $10 billion acquisition by Pfizer. Prior to Metsera, Mr. Lang served as Chief Business and Legal Officer at Lyell Immunopharma, Inc., and held several executive officer positions at Myovant Sciences, where he helped lead the company through Phase 3 clinical development, global approval and commercialization of Myfembree® and Orgovyx®. Mr. Lang also served as the Managing Director and General Manager of Myovant’s European operations in Basel Switzerland where he was responsible for all aspects of Myovant’s ex-US business operations. Earlier in his career Mr. Lang held roles of increasing seniority at Gilead Sciences, Inc., and was an attorney at Dechert, LLP. He received his B.A. in Classical Studies from Queen’s University at Kingston, Canada and his J.D. from the University of Pennsylvania Law School.
“I am excited to join Structure Therapeutics at this important stage as we move into Phase 3 development with one of the most promising late-stage assets in the competitive obesity landscape,” said Mr. Lang. “The Company’s mission and differentiated portfolio represent a compelling opportunity to deliver a complete pipeline of meaningful therapies to patients. I look forward to working with the team to further strengthen the Company’s operational foundation, execute on strategic priorities, and drive long-term value.”
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.
Story Continues
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company’s future plans and prospects; and any expectations regarding the potential benefits, tolerability and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience, expected effects and future application of aleniglipron and any other of the Company’s investigational compounds. In addition, when or if used in this press release, the words and phrases “anticipated,” “believe,” “expect,” “may,” “on track,” “plan,” “potential,” “suggests,” “to be,” “to begin,” “will,” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: risks and uncertainties related to potential delays in the commencement, enrollment and completion of the Company’s planned clinical studies; the Company’s ability to advance aleniglipron, ACCG-2671, ACCG-3535, ANPA-0073, LTSE-2578, and its other therapeutic candidates, obtain regulatory approval of, and ultimately commercialize the Company’s therapeutic candidates; competitive products or approaches limiting the commercial value of the Company’s product candidates; the Company’s ability to fund development activities and achieve development goals; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s latest Annual Report on Form 10-K and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com
Jun Yoon
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
View Comments
- Pfizer Reshapes Portfolio With Seagen And Metsera As COVID Winds Shift
Apr 8, 2026
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
Pfizer (NYSE:PFE) is accelerating its transformation with acquisitions of Seagen and Metsera to expand in oncology and anti obesity treatments. The company is dealing with lower COVID related revenues and the halt of a key COVID vaccine trial while advancing mRNA and Lyme vaccine programs. Pfizer reports a pipeline of more than 100 candidates, alongside cost cutting efforts and balance sheet adjustments during this transition phase.
For investors watching large pharma, Pfizer now sits at the intersection of established drug franchises and newer therapeutic areas. The Seagen and Metsera deals push the company further into oncology and metabolic disease, while its COVID franchise faces weaker demand and a stopped trial that could affect expectations around that segment. At the same time, Lyme vaccine progress and work in rare disease and mRNA reflect a broader shift in where research dollars are going.
Looking ahead, the key questions for NYSE:PFE holders center on how quickly these acquired and in house programs can move through the pipeline and how they might offset pressure from COVID products and upcoming patent expirations. Volatile sentiment around the stock ties back to this mix of new clinical catalysts, cost cuts, and uncertainty around legacy products. As a result, news flow on trial readouts and integration of recent deals is likely to matter. Investors may want to track how management prioritizes capital between further deals, dividends, and debt reduction as this transition continues.
Stay updated on the most important news stories for Pfizer by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Pfizer.NYSE:PFE Earnings & Revenue Growth as at Apr 2026
📰 Beyond the headline: 4 risks and 1 thing going right for Pfizer that every investor should see.
Pfizer’s push to buy Seagen for US$43b and Metsera for up to US$10b marks a clear shift away from pandemic driven products toward oncology and anti obesity drugs, where peers such as Eli Lilly, Novo Nordisk, Merck, and Bristol Myers Squibb are also active. At the same time, declining COVID related revenues, a halted COVID vaccine trial, and the patent dispute around Paxlovid show how dependent earnings were on pandemic products and how contested that space has become. Management is trying to bridge that gap with a pipeline of more than 100 candidates, including mRNA and Lyme vaccines, while running a US$7.2b cost savings program and closing sites like South San Francisco. For you as an investor, the question is whether the cash outlay, extra debt, and integration work for Seagen and Metsera will be offset by future oncology and obesity products quickly enough to handle patent expirations and lower COVID demand.
Story Continues
How This Fits Into The Pfizer Narrative
The Seagen and Metsera deals line up with the narrative’s focus on oncology, obesity, and higher value biologics as long term growth drivers supported by business development. Relying on acquisitions and out licensing to reshape the portfolio could challenge the idea of smooth execution, especially with regulatory pressures and a patent cliff already highlighted in the narrative. The combination of COVID demand uncertainty, site closures, and the Enanta legal appeal around Paxlovid is not fully captured in the growth and margin assumptions described in the narrative.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Pfizer to help decide what it's worth to you.
The Risks and Rewards Investors Should Consider
⚠️ Execution and timing risk around large acquisitions, with Seagen and Metsera needing substantial investment and integration while Pfizer is also cutting costs and closing research sites. ⚠️ Legal, regulatory, and pricing pressure, including the Enanta appeal on Paxlovid, potential drug pricing actions, and analyst flagged concerns about earnings, debt coverage, and dividend sustainability. 🎁 Exposure to large markets in oncology and obesity, where Seagen’s cancer portfolio and Metsera’s GLP 1 assets widen Pfizer’s reach alongside existing competitors like Eli Lilly, Novo Nordisk, and Merck. 🎁 A broad pipeline of more than 100 candidates and a reported valuation discount in some analyses, giving scope for sentiment to improve if key trials and product launches land as planned.
What To Watch Going Forward
From here, focus on how quickly Pfizer integrates Seagen and closes the Metsera deal, and whether trial readouts for oncology, obesity, mRNA, and Lyme vaccines hit their timelines. Watch any updates on COVID product demand, the Paxlovid patent case, and U.S. pricing policy, because these shape cash flows used to fund deals and the US$7.2b cost savings plan. It is also worth tracking analyst commentary around dividend coverage, debt levels, and upcoming patent expirations to see if the new portfolio is keeping pace with older products rolling off.
To ensure you're always in the loop on how the latest news impacts the investment narrative for Pfizer, head to the community page for Pfizer to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PFE.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- IP Group shares jump 9% as Metsera deal drives return to growth
Mar 17, 2026 · proactiveinvestors.co.uk
Shares in IP Group PLC (LSE:IPO) rose 9% to 53.5p on Monday after the company reported net asset value per share climbing to 110.4p, with total NAV reaching £975.1 million. The recovery was driven largely by Pfizer's acquisition of Metsera, a biotechnology company developing obesity treatments.
- IP Group CEO on 2025 highlights, NAV uplift, Pfizer royalties & capital allocation
Mar 16, 2026
IP Group PLC (LSE:IPO) CEO Greg Smith talked with Proactive's Stephen Gunnion about the company’s 2025 results, highlighting 13% growth in NAV per share and the strategic developments across its portfolio. The discussion focused on how IP Group’s exposure to Pfizer’s acquisition of Metsera could generate significant long-term royalty income for shareholders.
Smith explained that the company licenses the fundamental intellectual property behind an anti-obesity programme to Pfizer following the pharmaceutical giant’s acquisition of Metsera. The exposure has already been recognised with a £130 million asset valuation, equivalent to around 14p per share.
The conversation also covered several portfolio milestones during 2025. These included the successful IPO of Hinge Health on the New York Stock Exchange, which generated strong returns for IP Group, delivering approximately 50 times the company’s original investment after exiting its position. Another key development was the sale of Monolith to Nasdaq-listed CoreWeave, bringing additional proceeds and further payments expected in 2026.
Smith also discussed funding activity across the portfolio, including Artios Pharma’s $100 million Series D financing and a £100 million raise by autonomous vehicle company Oxa, backed by investors including the National Wealth Fund and Nvidia’s venture arm.
Alongside investments, IP Group has continued to return capital to shareholders through share buybacks, while targeting £250 million in exits by the end of 2027.
For more insights from company leaders and market updates, visit the Proactive YouTube channel, give this video a like, subscribe, and enable notifications so you never miss future interviews.
#IPGroup #IPGroupPLC #GregSmith #LSEIPO #Pfizer #BiotechInvesting #VentureCapital #UKTech #HingeHealth #Oxa #Artios #HealthcareInnovation #GrowthInvesting #StockMarketUK
View Comments
- Pfizer Secures $495 Million China Obesity Drug Deal
Feb 24, 2026
This article first appeared on GuruFocus.
Pfizer (NYSE:PFE) is stepping deeper into the global weight loss race, striking a deal with Hangzhou Sciwind Bioscience for exclusive commercialization rights to ecnoglutide in mainland China, in an agreement valued at up to $495 million. The therapy has already been approved in China for diabetes and is currently under regulatory review for obesity, positioning Pfizer to potentially enter one of the world's fastest-growing metabolic markets. According to company statements, obesity affects 14.1% of Chinese adults and has been prioritized under the government's Healthy China campaign, framing the opportunity as both commercial and policy-aligned.
Warning! GuruFocus has detected 5 Warning Signs with PFE. Is PFE fairly valued? Test your thesis with our free DCF calculator.
The transaction comes as Pfizer works to reestablish growth drivers following waning demand for its Covid-19 vaccine and mounting competitive pressures on several top medicines. The company has been actively expanding its obesity ambitions, including a $10 billion acquisition of Metsera Inc. after a bidding contest with Novo Nordisk (NYSE:NVO), as well as licensing an experimental drug last year from a unit of Shanghai Fosun Pharmaceutical Group. Alexandre de Germay, Pfizer's chief international commercial officer, acknowledged ahead of the announcement that the company had lost our focus during the pandemic period, underscoring why rebuilding in high-demand therapeutic areas such as obesity could be central to its forward strategy. China represented 4% of Pfizer's total revenue as of 2024, and the local business has undergone multiple restructurings in recent years.
Ecnoglutide operates in the GLP-1 class, similar to Novo Nordisk's Ozempic, by mimicking a hormone that regulates blood sugar and appetite, though Sciwind has indicated its molecular structure may offer potential advantages over other GLP-1 receptor agonists. In a late-stage study, the drug produced weight loss results on par with Eli Lilly's (NYSE:LLY) Zepbound. Under the agreement, Sciwind will continue handling development, registration, manufacturing and supply, while Pfizer takes responsibility for commercialization across mainland China. The competitive landscape includes global pharmaceutical leaders as well as domestic players such as Innovent Biologics, suggesting Pfizer's latest move could represent a calculated effort to secure relevance in a segment that is reshaping large-cap pharma growth expectations.
View Comments
- Pfizer Pipeline Shifts With Obesity Push And BREAKWATER Cancer Results
Feb 24, 2026
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Pfizer (NYSE:PFE) has expanded its obesity drug ambitions with the acquisition of Metsera and more than 20 active clinical studies in weight management. The company also reported promising pivotal BREAKWATER trial results for BRAFTOVI in metastatic colorectal cancer. Together, these developments highlight fresh activity in Pfizer's pipeline across both metabolic disease and oncology.
For investors watching NYSE:PFE, these moves come with the stock trading around $27.06 and mixed longer term returns, including a 7.5% gain year to date and an 8.9% return over the past year, alongside a 20.5% decline over three years. The combination of obesity drug work and BREAKWATER trial progress provides new information to weigh against that share price history.
From here, the scale of Pfizer's obesity studies and the BREAKWATER colorectal cancer data may influence how you think about the breadth and focus of its drug pipeline. As more clinical results arrive and regulatory paths become clearer, investors can reassess how these programs fit into Pfizer's overall mix of risks and opportunities.
Stay updated on the most important news stories for Pfizer by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Pfizer.NYSE:PFE Earnings & Revenue Growth as at Feb 2026
📰 Beyond the headline: 4 risks and 2 things going right for Pfizer that every investor should see.
Quick Assessment
⚖️ Price vs Analyst Target: At US$27.06 versus a consensus target of about US$28.56, Pfizer trades roughly 5% below where analysts sit, which is within a fair range. ✅ Simply Wall St Valuation: Simply Wall St estimates the shares are trading about 58.4% below their fair value, which is a clear valuation gap to investigate. ✅ Recent Momentum: A 30 day return of about 5.5% shows the share price has recently moved higher.
To assess whether it is the right time to buy, sell or hold Pfizer, you can review Simply Wall St's company report for the latest analysis of Pfizer's Fair Value.
Key Considerations
📊 The Metsera deal and BREAKWATER trial results point to fresh activity in both obesity and oncology, which may help diversify Pfizer's earnings base over time. 📊 It may be useful to watch how obesity trial readouts, colorectal cancer regulatory milestones and the current 19.9x P/E versus the sector average play into sentiment around the pipeline. ⚠️ The dividend is flagged as not well covered by earnings or free cash flow, so any large R&D or acquisition spend could keep payout risk in focus.
Story Continues
Dig Deeper
For the full picture including more risks and potential rewards, you can review the complete Pfizer analysis. You can also visit the community page for Pfizer to see how other investors believe this latest news will impact the company's narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PFE.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
